Navigating midlife and menopause often involves exploring various options to support well-being. Black cohosh is one such botanical that women frequently consider. Understanding the regulatory landscape and safety information surrounding black cohosh is an important part of making informed personal health choices.
While black cohosh has been a subject of research, it’s crucial to be aware of the FDA’s perspective and any associated warnings. This article aims to provide clear, evidence-based information on black cohosh supplements, focusing on safety and regulatory considerations.
Is Black Cohosh Approved by the FDA?
In the United States, dietary supplements, including black cohosh, are regulated by the FDA under the Dietary Supplement Health and Education Act (DSHEA) of 1994. It’s important to understand that DSHEA places dietary supplements in a different category than prescription or over-the-counter medications. Unlike pharmaceutical drugs, dietary supplements do not require pre-market approval from the FDA before they can be sold.
This means that the FDA does not “approve” black cohosh supplements in the same way it approves a new drug. Instead, manufacturers are responsible for ensuring the safety and labeling accuracy of their products before they go to market. The FDA’s role primarily involves monitoring the safety of supplements after they are on the market and taking action against unsafe products or those with false or misleading claims.
FDA and Liver Health Concerns with Black Cohosh
One of the most significant safety concerns that has prompted attention from regulatory bodies, including the FDA, is the potential for liver-related issues associated with black cohosh. There have been case reports linking black cohosh consumption to liver toxicity [1]. These reports describe various degrees of liver injury, though a definitive causal link has been challenging to establish in all instances.
The United States Pharmacopeia (USP), a nonprofit standard-setting organization rather than a government agency, reviewed the black cohosh liver case reports in 2008[1]. Its Dietary Supplement Information Expert Committee analyzed 30 non-duplicate reports of liver damage and graded each one on the Naranjo causality scale. All 30 came out as only possible causality, none reached probable or certain, and the committee noted that the clinical pharmacokinetic and animal toxicology data did not reveal unfavorable information about black cohosh[1]. On that basis USP reversed its own 2002 decision, which had required no such statement, and recommended that black cohosh products be labeled with the cautionary statement “Discontinue use and consult a healthcare practitioner if you have a liver disorder or develop symptoms of liver trouble, such as abdominal pain, dark urine, or jaundice”[1][2].
It is worth being exact about who requires what, because this point is widely misstated. That cautionary statement is a USP recommendation, not a federal rule. The U.S. Food and Drug Administration does not require a liver warning on black cohosh product labels[2]. Australia went further: its Therapeutic Goods Administration has required products containing black cohosh to carry the statement “Warning: Black cohosh may harm the liver in some individuals. Use under the supervision of a healthcare professional” since 2007[2]. In practical terms, a bottle bought in the United States may carry a liver caution voluntarily or carry none at all, and both are legal, so the absence of a warning on a US label tells you nothing about the product.
Labeling and Quality of Black Cohosh Supplements
The FDA’s regulations for dietary supplements emphasize that product labels should not make claims to diagnose, mitigate, treat, or cure a disease. Instead, labels can make structure/function claims, such as “supports menopausal comfort,” provided they are truthful and not misleading. However, ensuring the quality and purity of black cohosh supplements can be a challenge.
Studies have indicated that not all black cohosh products on the market contain the advertised ingredients or concentrations. Some products may be adulterated with other plant species or contain little to no active black cohosh components. This is a measured problem for this herb specifically, not a hypothetical one: a 2024 review in Natural Product Reports pooled 78 published studies covering 2,995 samples across five popular herbs and found that 42.2 percent of the 322 black cohosh rhizome samples had been reported as adulterated or mislabeled, the second-highest rate of the five behind ginkgo leaf[3]. That review also found that products sold as licensed or registered herbal medicines carried a lower risk of adulteration than the same ingredient sold as a dietary supplement[3]. This inconsistency in product quality can make it difficult for consumers to know what they are truly taking and may complicate assessments of safety and effectiveness. The FDA does have the authority to take action against manufacturers whose products are mislabeled or adulterated.
General Safety Considerations and Adverse Effects
Beyond liver concerns, other adverse effects have been reported with black cohosh use. These can include gastrointestinal upset, headache, and rash [4]. While generally considered mild, any unusual or persistent symptoms should be discussed with a healthcare provider.
It’s also important to consider potential interactions with other medications. Black cohosh may interact with certain drugs, including hormone therapies [5]. Women who are taking prescription medications or other supplements should consult their healthcare provider before adding black cohosh to their regimen to avoid potential adverse interactions.
The FDA’s Role in Post-Market Surveillance
Since dietary supplements do not undergo pre-market approval, the FDA’s primary mechanism for ensuring safety is through post-market surveillance. This involves monitoring adverse event reports submitted by consumers, healthcare professionals, and manufacturers. When the FDA identifies a pattern of adverse events or serious safety concerns, it can take regulatory action.
Actions can include issuing warning letters to manufacturers, requiring product recalls, or pursuing enforcement actions against companies that violate regulations. The FDA also provides guidance to the industry to help ensure compliance with good manufacturing practices, which aim to ensure the identity, purity, quality, strength, and composition of dietary supplements.
References
- United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity. Menopause (New York, N.Y.), 2008
- Black Cohosh: Fact Sheet for Health Professionals. National Institutes of Health, Office of Dietary Supplements
- Estimating the extent of adulteration of the popular herbs black cohosh, echinacea, elder berry, ginkgo, and turmeric: its challenges and limitations. Natural Product Reports, 2024
- Review of black cohosh-induced toxicity and adverse clinical effects. Journal of environmental science and health. Part C, Toxicology and carcinogenesis, 2025
- Hormone Therapy and Other Treatments for Symptoms of Menopause. American family physician, 2016
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
